Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Royalty Pharma plc (RPRX)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/03/2023
144
Form 144 - Report of proposed sale of securities:
10/03/2023
144
Form 144 - Report of proposed sale of securities:
08/09/2023
144
Form 144 - Report of proposed sale of securities:
08/08/2023
10-Q
Quarterly Report for the period ended June 30, 2023
08/08/2023
8-K
Quarterly results
Docs:
"
ROYALTY PHARMA REPORTS SECOND QUARTER 2023 RESULTS
"
07/12/2023
144
Form 144 - Report of proposed sale of securities:
07/03/2023
144
Form 144 - Report of proposed sale of securities:
07/03/2023
144
Form 144 - Report of proposed sale of securities:
06/02/2023
144
Form 144 - Report of proposed sale of securities:
06/02/2023
144
Form 144 - Report of proposed sale of securities:
05/22/2023
144
Form 144 - Report of proposed sale of securities:
05/09/2023
10-Q
Quarterly Report for the period ended March 31, 2023
05/09/2023
8-K
Quarterly results
Docs:
"
ROYALTY PHARMA REPORTS FIRST QUARTER 2023 RESULTS
"
04/27/2023
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/28/2023
8-K
Quarterly results
03/15/2023
8-K
Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
ROYALTY PHARMA RAISES FULL YEAR 2023 GUIDANCE • Royalty Pharma now expects 2023 Adjusted Cash Receipts to be between $2,850 million and $2,950 million, excluding contributions from future transactions.
"
02/13/2023
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023
5
Form 5 - Annual statement of changes in beneficial ownership of securities:
02/10/2023
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023
SC 13G/A
FMR LLC reports a 10% stake in ROYALTY PHARMA PLC
02/09/2023
SC 13G/A
VANGUARD GROUP INC reports a 8.1% stake in Royalty Pharma plc Class A
02/09/2023
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 1.6% stake in Royalty Pharma plc
01/09/2023
8-K
Quarterly results
12/01/2022
8-K
Quarterly results
11/22/2022
APP ORDR
Form APP ORDR - 40-APP Order:
11/08/2022
10-Q
Quarterly Report for the period ended September 30, 2022
11/08/2022
8-K
Quarterly results
Docs:
"
ROYALTY PHARMA REPORTS THIRD QUARTER 2022 RESULTS
"
10/31/2022
APP NTC
Form APP NTC - 40-APP Notice:
10/04/2022
SC 13D/A
Giuliani Mario Germano reports a 10% stake in Royalty Pharma plc
10/03/2022
8-K
Quarterly results
09/20/2022
40-APP
Form 40-APP - Application for exemption and other relief filed under the Investment Company Act of 1940:
08/11/2022
SC 13D/A
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/04/2022
10-Q
Quarterly Report for the period ended June 30, 2022
08/04/2022
8-K
Quarterly results
Docs:
"
ROYALTY PHARMA REPORTS SECOND QUARTER 2022 RESULTS
"
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy